Talkspace, Inc. TALK R2KR3KPHARMA
Company Overview
Talkspace, Inc., together with its subsidiaries, operates as a virtual behavioral healthcare company that connects patients with licensed mental health providers in the United States. The company provides psychotherapy and psychiatry services to treat various mental health conditions, such as depression, anxiety, trauma, and other fields of human challenges by operating an online platform for one-on-one therapy delivered through messaging, audio, and video channels. It serves health insurance plans and employee assistance programs, direct-to-enterprise customers, and individual subscribers. The company was formerly known as Groop Internet Platform Inc. and changed its name to Talkspace, Inc. in June 2021. The company was founded in 2012 and is headquartered in New York, New York.
Why Investors Should Care
Revenue has grown at a 34.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $228.87M (+22.0% YoY); net profit $7.79M.
- Trailing 12 Months Year-on-year growth — revenue +18.2%, earnings +578.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 34.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 34.78% |
| 1 Year: | 18.20% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 578.83% |
Stock Price Performance
| 1 Year: | +103.49% |
| 6 Months: | +37.08% |
| 3 Months: | +0.96% |
| 1 Month: | +0.77% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.15 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 34.8% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TALK Talkspace, Inc. R2KR3KPHARMA | 5.25 | - | $879.44M | 0.00% | 2.68% | 1.03% | 34.78% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 17.88M | 21.50M | 27.16M | 30.98M | 26.36M | 30.15M | 29.84M | 29.33M | 33.34M | 35.65M | 38.65M | 45.42M | 46.06M | 47.40M | 52.18M | 54.31M | 59.38M | 63.00M | 61.68M | 61.67M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.79M | 30.92M | 34.74M | 36.08M | 36.06M | - |
| Gross Profit | - | 12.31M | 15.09M | 17.34M | 19.29M | 14.17M | 15.02M | 14.55M | 14.60M | 16.75M | 17.81M | 18.85M | 21.73M | 20.95M | 21.62M | 23.39M | 23.39M | 24.64M | 26.92M | 25.61M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.48M | 25.18M | 22.44M | 23.09M | 32.74M | - |
| Operating Income | - | -641.00K | 2.40M | -12.56M | -27.56M | 25.23M | 21.21M | 21.07M | 19.85M | 9.04M | -6.41M | -5.18M | -1.68M | -3.49M | 99.00K | -1.08M | -1.79M | 2.20M | 3.83M | -7.13M | -2.11M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -419.00K | -1.07M | 2.88M | 4.65M | -5.59M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 441.00K | -465.00K | 3.28M | 5.12M | -6.18M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 123.00K | 76.00K | 25.00K | 350.00K | 124.00K | - |
| Net Income | -7.90M | -646.00K | -2.69M | -12.74M | -30.44M | 1.50M | -20.36M | -23.02M | -17.98M | -8.76M | -4.70M | -4.41M | -1.47M | -474.00K | 1.87M | 318.00K | -541.00K | 3.25M | 4.76M | -6.31M | -1.52M |
| Diluted EPS | - | - | -0.20 | - | 1.15 | 0.01 | -0.13 | -0.15 | -0.11 | -0.05 | -0.03 | -0.03 | -0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.02 | 0.03 | -0.04 | -0.01 |
| R&D Expense | - | 2.40M | 2.20M | 2.96M | 4.78M | 4.28M | 5.04M | 5.58M | 6.07M | 5.35M | 4.17M | 4.18M | 3.74M | 2.09M | 2.30M | 2.84M | 2.56M | 1.78M | - | 2.66M | 2.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 38.18M | 76.19M | 113.67M | 119.57M | 150.04M | 187.59M | 228.87M |
| Gross Profit | 20.14M | 49.84M | 66.77M | 60.34M | 74.38M | 85.84M | - |
| Operating Income | -29.43M | -21.98M | -93.92M | -83.16M | -23.21M | -4.50M | 3.15M |
| Net Income | -29.09M | -22.37M | -62.74M | -79.67M | -19.18M | 1.15M | 7.79M |
| Diluted EPS | - | -1.67 | -0.72 | -0.51 | -0.12 | 0.01 | 0.04 |
| R&D Expense | 12.00M | 9.58M | 15.92M | 21.66M | 17.07M | 10.28M | 9.54M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 32.87M | 223.61M | 156.25M | 142.22M | 138.68M | 134.86M |
| Total Equity | -54.21M | -79.60M | -98.90M | 192.27M | 127.54M | 118.65M | 117.39M | 117.02M |
| Cash & Equivalents | 9.46M | 39.63M | 13.25M | 198.26M | 138.54M | 123.91M | 76.69M | 37.35M |
| Total Liabilities | - | - | 20.49M | 31.33M | 28.72M | 23.57M | 21.28M | 17.85M |
| Current Liabilities | - | - | 20.49M | 27.18M | 27.32M | 21.65M | 19.02M | 17.40M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.19M | -15.18M | -65.71M | -61.08M | -16.39M | 11.29M | 8.53M |
| Investing Cash Flow | -138.00K | -11.30M | -663.00K | -317.00K | -141.00K | -46.31M | -28.88M |
| Financing Cash Flow | 51.50M | 94.00K | 251.38M | 1.68M | 1.90M | -12.19M | -19.00M |
| Capital Expenditure | -138.00K | -126.00K | -663.00K | -350.00K | -151.00K | - | - |
| Free Cash Flow | -21.33M | -15.30M | -66.37M | -61.43M | -16.54M | - | - |
| Share Buybacks | - | - | - | 0 | 0 | 11.00M | 17.20M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 52.7% | 65.4% | 58.7% | 50.5% | 49.6% | 45.8% | - |
| Operating Margin % | -77.1% | -28.9% | -82.6% | -69.5% | -15.5% | -2.4% | 1.4% |
| Net Margin % | -76.2% | -29.4% | -55.2% | -66.6% | -12.8% | 0.6% | 3.4% |
| ROE % | 36.5% | 22.6% | -32.6% | -62.5% | -16.2% | 1.0% | 6.7% |
| ROCE % | - | -177.5% | -47.8% | -64.5% | -19.2% | -3.8% | 2.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 6.72% | 11.26M | $59.12M |
| 2 | Hudson Executive Capital, LP | 5.85% | 9.80M | $51.43M |
| 3 | Balyasny Asset Management LP | 4.09% | 6.86M | $36.00M |
| 4 | Nexpoint Asset Management, L.P. | 4.05% | 6.79M | $35.63M |
| 5 | FIL LTD | 4.00% | 6.70M | $35.18M |
| 6 | Vanguard Capital Management LLC | 3.61% | 6.05M | $31.75M |
| 7 | Magnetar Financial LLC | 2.60% | 4.35M | $22.83M |
| 8 | Deutsche Bank AG | 2.47% | 4.14M | $21.75M |
| 9 | Geode Capital Management, LLC | 2.46% | 4.13M | $21.68M |
| 10 | Goldman Sachs Group Inc | 2.30% | 3.86M | $20.24M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TALK
Netflix Stock Rebound Fuels Ad Growth Talk: A Sign of More Upside? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOTUFrWFZkZWNWZXVTZFRXV2Z1aUFaajF3RlZNaHBNcnVuMXk2WndkenNnYzUzQlJlbzBHWTdmbnVIT240QzA1SXRPNlJfTGwwbVlENHJGRE1uNFNlYXJmWEc5elBSX00xaElNbTFReVNYWDNUaG4tZlI3MElMZmRQeEZTSWpFOExhcmhJVj…
'Fast Money' traders talk stock moves in Sandisk and Micron - CNBC
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPRVo2Z0pKMFB2X3hZUnN6MVg2a0RvWnRXdXNReC12OEhKQ0xIYk12My1GUVJPQzBlZVZvS1ZDTzA0Z2ZFNmV6Yng4NkJsMHRLYnVkN01ob29XTHV2WWw4OGg1a09zV2xKNTFodlVoc1JudlBkbzNQenFPQWRobjRQMlkwbktBVVdsMkZ4Mm…
Varonis Stock Jumped 10% on Buyout Talk. The Street’s Targets Say There’s More Room. - TIKR.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQVWlSYm1nUzE3VHJMWEt2UWV2LWxEUFcyeExQRm9sNngxX21IU2tJZWJRZGhFVzBldkJRSnVQM0lfX0daekFOSi1qdzdieXkxMTRYcUg3cV9ZYVhnX0FYWVBkS2hVcmxUTUJwMEV1WlNLSFNndEpLbFNkcnpiT0lnLWxQT1U1SEg1S1Bjel…
Talkspace A Stock (TALK) - Quote Nasdaq - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTE9fODFqRjNuNkh5VkIxR3hXWXVQQWpQN3BZOV9yVW5UT2FmUGlzZXhTdHAtZkc0MkIxc252Y3UwN1JfaGRveXdMQVZGOXJab0dZRnhMNU15WFpQWEszTV9LT0VnZkstZXpLZDR0ZlZpQzdYVTQ?oc=5" target="_blank">Talkspace A …
BHP Stock Faces Monday Test as WAIO Partnership Talk Reaches $14.7 Billion Earnings Engine - TechStock²
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPbUl0enNVNnE1UDBQOHBWZjBaMDFxUXJjR1ctcjR2dnRiYnpSUS03X0ZEYzBFNDRDWXh1TS1rZjBKRVJnYmRybWZEYmZDc0pmVjM1bDVsczBzQXVLNzNWbkd3SFhTVnZZY1FYeVZ6eU9Uc09uNk1raERGVmpuWmk5cXdUOVB6S1huN3JIX0…
Talkspace Inc (NASDAQ: TALK) Share Price, TALK Stock News, TALK Share Price & Updates - Kalkine
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE0weGJZVGh5RWlHNFFRNmVzQnNoZ29pdWFRMElYWFdndGg5YXM1R1REQUtsekxkZjk2bkkyWmhIZ0Z1T0dScHhSQVBjYjd0MGdCUk9tWGFB?oc=5" target="_blank">Talkspace Inc (NASDAQ: TALK) Share Price, TALK Stoc…
TALK — Frequently Asked Questions
What is the current share price of Talkspace, Inc. (TALK)?
As of 2026-09-07 16:24 PDT, Talkspace, Inc. (TALK) trades at $5.25 on NasdaqCM. Its 52-week range is $2.49 to $5.25.
What is the market capitalisation of TALK?
Talkspace, Inc. (TALK) has a market capitalisation of $879.44M on NasdaqCM.
What is the return on equity (ROE) of TALK?
TALK has a return on equity (ROE) of 1.03%. Its return on capital employed (ROCE) is 2.68%.
Is TALK a good stock to buy?
This page provides a data-driven analysis of Talkspace, Inc. (TALK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.